麗珠醫藥(01513.HK):與中科院合研新冠疫苗加強劑對於Omicron產生良好保護力
麗珠醫藥(01513.HK)公布,公司與中科院合研的重組新型冠狀病毒融合蛋白疫苗(V-01)已完成序貫加強Ⅲ期臨床試驗的中期主資料分析,結果顯示注射V-01加強劑的和接種兩針新型冠狀病毒滅活疫苗的人對比,年發病率分別為6.73%和12.80%。
公司表示,本次試驗全部有效送檢標本中60個的新冠病毒基因分型一代測序均為Omicron,其餘仍在進行二代測序,表明V-01序貫加強對於Omicron感染導致的新型冠狀病毒病可產生良好的保護力,同時,未發現有值得關注的安全性問題。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.